VEGFA and hepatocellular carcinoma: Monoclonal antibodies (bevacizumab and ramucirumab) and small-molecule inhibitors (sorafenib and lenvatinib) targeting the hypoxia-responsive gene VEGF and its receptors have become first-line treatments for advanced HCC (Llovet et al., 2021b).